Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of iptacopan in C3 glomerulopathy
MOH_2022-12-01_012210Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in Complement 3 glomerulopathy (C3G), sponsored by Novartis. Started Jan 2023; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on MOH_2022-12-01_012210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-01_012210.